25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Novonesis (Novozymes) A/S
Buy, Hold or Sell?

Let's analyze Novonesis together

I guess you are interested in Novonesis (Novozymes) A/S. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Novonesis (Novozymes) A/S. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Novonesis (Novozymes) A/S

I send you an email if I find something interesting about Novonesis (Novozymes) A/S.

1. Quick Overview

1.1. Quick analysis of Novonesis (30 sec.)










1.2. What can you expect buying and holding a share of Novonesis? (30 sec.)

How much money do you get?

How much money do you get?
kr2.27
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
kr260.68
Expected worth in 1 year
kr269.61
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
kr25.14
Return On Investment
6.0%

For what price can you sell your share?

Current Price per Share
kr416.40
Expected price per share
kr383.34 - kr485.90
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Novonesis (5 min.)




Live pricePrice per Share (EOD)
kr416.40
Intrinsic Value Per Share
kr-33.53 - kr44.27
Total Value Per Share
kr227.14 - kr304.95

2.2. Growth of Novonesis (5 min.)




Is Novonesis growing?

Current yearPrevious yearGrowGrow %
How rich?$14.9b$14.8b$128.4m0.9%

How much money is Novonesis making?

Current yearPrevious yearGrowGrow %
Making money$423.3m$514.6m-$91.2m-21.6%
Net Profit Margin16.9%20.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Novonesis (5 min.)




2.4. Comparing to competitors in the Specialty Chemicals industry (5 min.)




  Industry Rankings (Specialty Chemicals)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Novonesis?

Welcome investor! Novonesis's management wants to use your money to grow the business. In return you get a share of Novonesis.

First you should know what it really means to hold a share of Novonesis. And how you can make/lose money.

Speculation

The Price per Share of Novonesis is kr416.40. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Novonesis.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Novonesis, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr260.68. Based on the TTM, the Book Value Change Per Share is kr2.23 per quarter. Based on the YOY, the Book Value Change Per Share is kr36.73 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr4.05 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Novonesis.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps1.030.2%1.030.2%1.250.3%1.080.3%1.040.3%
Usd Book Value Change Per Share0.310.1%0.310.1%5.141.2%1.480.4%0.840.2%
Usd Dividend Per Share0.570.1%0.570.1%0.520.1%0.520.1%0.440.1%
Usd Total Gains Per Share0.880.2%0.880.2%5.661.4%2.000.5%1.270.3%
Usd Price Per Share51.95-51.95-49.27-54.20-47.81-
Price to Earnings Ratio50.39-50.39-39.31-50.61-45.98-
Price-to-Total Gains Ratio59.05-59.05-8.70--69.61--23.13-
Price to Book Ratio1.42-1.42-1.36-1.70-1.56-
Price-to-Total Gains Ratio59.05-59.05-8.70--69.61--23.13-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share58.296
Number of shares17
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.570.52
Usd Book Value Change Per Share0.311.48
Usd Total Gains Per Share0.882.00
Gains per Quarter (17 shares)14.9633.97
Gains per Year (17 shares)59.83135.88
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
139215035101126
2774311070201262
311664170105302398
415485230141403534
5193106290176504670
6231128350211604806
7270149410246705942
83081704702818061078
93471915303169071214
1038621359035110071350

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%22.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%8.02.00.080.0%16.06.00.072.7%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%22.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%8.02.00.080.0%16.06.00.072.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Novonesis (Novozymes) A/S compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.2342.2340%36.728-94%10.583-79%5.967-63%
Book Value Per Share--260.676260.6760%258.442+1%230.719+13%219.483+19%
Current Ratio--1.3031.3030%1.327-2%1.432-9%1.525-15%
Debt To Asset Ratio--0.4950.4950%0.492+1%0.477+4%0.430+15%
Debt To Equity Ratio--1.0041.0040%0.994+1%0.933+8%0.778+29%
Dividend Per Share--4.0504.0500%3.714+9%3.690+10%3.132+29%
Eps--7.3657.3650%8.952-18%7.708-4%7.445-1%
Free Cash Flow Per Share--3.0733.0730%2.718+13%5.267-42%5.895-48%
Free Cash Flow To Equity Per Share--3.0733.0730%-0.326+111%1.471+109%0.624+393%
Gross Profit Margin--1.0001.0000%0.382+162%0.538+86%0.504+98%
Intrinsic Value_10Y_max--44.269--------
Intrinsic Value_10Y_min---33.533--------
Intrinsic Value_1Y_max--5.593--------
Intrinsic Value_1Y_min--2.334--------
Intrinsic Value_3Y_max--15.923--------
Intrinsic Value_3Y_min--2.121--------
Intrinsic Value_5Y_max--25.190--------
Intrinsic Value_5Y_min---3.449--------
Market Cap170979249868.800+11%152378481331.200152378481331.2000%144494711884.800+5%158964713722.880-4%140224336768.000+9%
Net Profit Margin--0.1690.1690%0.209-19%0.202-16%0.207-18%
Operating Margin----0%0.264-100%0.215-100%0.246-100%
Operating Ratio--1.2071.2070%0.748+61%0.838+44%0.782+54%
Pb Ratio1.597+11%1.4241.4240%1.362+5%1.697-16%1.559-9%
Pe Ratio56.541+11%50.39050.3900%39.308+28%50.6110%45.985+10%
Price Per Share416.400+11%371.100371.1000%351.900+5%387.140-4%341.500+9%
Price To Free Cash Flow Ratio135.483+11%120.744120.7440%129.476-7%86.256+40%66.988+80%
Price To Total Gains Ratio66.261+11%59.05259.0520%8.701+579%-69.605+218%-23.134+139%
Quick Ratio--0.5150.5150%0.669-23%0.818-37%0.918-44%
Return On Assets--0.0140.0140%0.018-19%0.018-19%0.019-27%
Return On Equity--0.0290.0290%0.036-19%0.034-15%0.034-16%
Total Gains Per Share--6.2846.2840%40.442-84%14.273-56%9.099-31%
Usd Book Value--14985170690.00014985170690.0000%14856735320.000+1%13263092542.000+13%12617156608.000+19%
Usd Book Value Change Per Share--0.3130.3130%5.142-94%1.482-79%0.835-63%
Usd Book Value Per Share--36.49536.4950%36.182+1%32.301+13%30.728+19%
Usd Dividend Per Share--0.5670.5670%0.520+9%0.517+10%0.438+29%
Usd Eps--1.0311.0310%1.253-18%1.079-4%1.042-1%
Usd Free Cash Flow--176680000.000176680000.0000%156240000.000+13%302792000.000-42%338884000.000-48%
Usd Free Cash Flow Per Share--0.4300.4300%0.381+13%0.737-42%0.825-48%
Usd Free Cash Flow To Equity Per Share--0.4300.4300%-0.046+111%0.206+109%0.087+393%
Usd Market Cap23937094981.632+11%21332987386.36821332987386.3680%20229259663.872+5%22255059921.203-4%19631407147.520+9%
Usd Price Per Share58.296+11%51.95451.9540%49.266+5%54.200-4%47.810+9%
Usd Profit--423360000.000423360000.0000%514640000.000-18%443100000.000-4%427966000.000-1%
Usd Revenue--2505860000.0002505860000.0000%2457420000.000+2%2206092000.000+14%2076382000.000+21%
Usd Total Gains Per Share--0.8800.8800%5.662-84%1.998-56%1.274-31%
 EOD+4 -4MRQTTM+0 -0YOY+17 -195Y+13 -2310Y+14 -22

3.3 Fundamental Score

Let's check the fundamental score of Novonesis (Novozymes) A/S based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1556.541
Price to Book Ratio (EOD)Between0-11.597
Net Profit Margin (MRQ)Greater than00.169
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.515
Current Ratio (MRQ)Greater than11.303
Debt to Asset Ratio (MRQ)Less than10.495
Debt to Equity Ratio (MRQ)Less than11.004
Return on Equity (MRQ)Greater than0.150.029
Return on Assets (MRQ)Greater than0.050.014
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Novonesis (Novozymes) A/S based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.357
Ma 20Greater thanMa 50416.760
Ma 50Greater thanMa 100444.116
Ma 100Greater thanMa 200442.827
OpenGreater thanClose425.300
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Novonesis (Novozymes) A/S

Novonesis A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; warm water species, recirculating aquaculture system; animal health and nutrition solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions. Additionally, the company provides carbon capture, leather and textiles solutions; enzyme solutions, including corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; warm water species and recirculating aquaculture system solutions; human health solutions, comprising brain, oral, protective and immune, and gastrointestinal health solutions; ethanol, biodiesel, renewable diesel, education, wastewater, and sewage sludge, and renewable diesel solutions; agriculture and industry, biogas food waste, food waste, biocatalysis, cell culture, diagnostics, enzyme, and biogas solutions. Furthermore, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novonesis A/S was founded in 1925 and is based in Bagsvaerd, Denmark.

Fundamental data was last updated by Penke on 2024-11-17 21:17:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Novonesis earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Novonesis to the Specialty Chemicals industry mean.
  • A Net Profit Margin of 16.9% means that kr0.17 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Novonesis (Novozymes) A/S:

  • The MRQ is 16.9%. The company is making a huge profit. +2
  • The TTM is 16.9%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ16.9%TTM16.9%0.0%
TTM16.9%YOY20.9%-4.0%
TTM16.9%5Y20.2%-3.3%
5Y20.2%10Y20.7%-0.5%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ16.9%4.4%+12.5%
TTM16.9%3.7%+13.2%
YOY20.9%4.3%+16.6%
5Y20.2%5.7%+14.5%
10Y20.7%6.0%+14.7%
4.3.1.2. Return on Assets

Shows how efficient Novonesis is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Novonesis to the Specialty Chemicals industry mean.
  • 1.4% Return on Assets means that Novonesis generated kr0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Novonesis (Novozymes) A/S:

  • The MRQ is 1.4%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.4%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.4%TTM1.4%0.0%
TTM1.4%YOY1.8%-0.3%
TTM1.4%5Y1.8%-0.3%
5Y1.8%10Y1.9%-0.2%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4%1.1%+0.3%
TTM1.4%0.9%+0.5%
YOY1.8%1.1%+0.7%
5Y1.8%1.4%+0.4%
10Y1.9%1.6%+0.3%
4.3.1.3. Return on Equity

Shows how efficient Novonesis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Novonesis to the Specialty Chemicals industry mean.
  • 2.9% Return on Equity means Novonesis generated kr0.03 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Novonesis (Novozymes) A/S:

  • The MRQ is 2.9%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.9%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.9%TTM2.9%0.0%
TTM2.9%YOY3.6%-0.7%
TTM2.9%5Y3.4%-0.5%
5Y3.4%10Y3.4%0.0%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9%2.0%+0.9%
TTM2.9%1.8%+1.1%
YOY3.6%2.0%+1.6%
5Y3.4%2.6%+0.8%
10Y3.4%2.7%+0.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Novonesis (Novozymes) A/S.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Novonesis is operating .

  • Measures how much profit Novonesis makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Novonesis to the Specialty Chemicals industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Novonesis (Novozymes) A/S:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY26.4%-26.4%
TTM-5Y21.5%-21.5%
5Y21.5%10Y24.6%-3.2%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.9%-7.9%
TTM-5.3%-5.3%
YOY26.4%6.1%+20.3%
5Y21.5%7.4%+14.1%
10Y24.6%7.6%+17.0%
4.3.2.2. Operating Ratio

Measures how efficient Novonesis is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Specialty Chemicals industry mean).
  • An Operation Ratio of 1.21 means that the operating costs are kr1.21 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Novonesis (Novozymes) A/S:

  • The MRQ is 1.207. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.207. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.207TTM1.2070.000
TTM1.207YOY0.748+0.460
TTM1.2075Y0.838+0.369
5Y0.83810Y0.782+0.057
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2071.328-0.121
TTM1.2071.204+0.003
YOY0.7481.073-0.325
5Y0.8381.150-0.312
10Y0.7821.069-0.287
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Novonesis (Novozymes) A/S.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Novonesis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Specialty Chemicals industry mean).
  • A Current Ratio of 1.30 means the company has kr1.30 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Novonesis (Novozymes) A/S:

  • The MRQ is 1.303. The company is just able to pay all its short-term debts.
  • The TTM is 1.303. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.303TTM1.3030.000
TTM1.303YOY1.327-0.024
TTM1.3035Y1.432-0.129
5Y1.43210Y1.525-0.093
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3031.803-0.500
TTM1.3031.863-0.560
YOY1.3271.921-0.594
5Y1.4321.954-0.522
10Y1.5251.891-0.366
4.4.3.2. Quick Ratio

Measures if Novonesis is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Novonesis to the Specialty Chemicals industry mean.
  • A Quick Ratio of 0.52 means the company can pay off kr0.52 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Novonesis (Novozymes) A/S:

  • The MRQ is 0.515. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.515. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.515TTM0.5150.000
TTM0.515YOY0.669-0.153
TTM0.5155Y0.818-0.303
5Y0.81810Y0.918-0.100
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5150.825-0.310
TTM0.5150.883-0.368
YOY0.6691.074-0.405
5Y0.8181.133-0.315
10Y0.9181.165-0.247
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Novonesis (Novozymes) A/S.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Novonesis assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Novonesis to Specialty Chemicals industry mean.
  • A Debt to Asset Ratio of 0.49 means that Novonesis assets are financed with 49.5% credit (debt) and the remaining percentage (100% - 49.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Novonesis (Novozymes) A/S:

  • The MRQ is 0.495. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.495. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.495TTM0.4950.000
TTM0.495YOY0.492+0.003
TTM0.4955Y0.477+0.018
5Y0.47710Y0.430+0.047
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4950.426+0.069
TTM0.4950.423+0.072
YOY0.4920.427+0.065
5Y0.4770.428+0.049
10Y0.4300.432-0.002
4.5.4.2. Debt to Equity Ratio

Measures if Novonesis is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Novonesis to the Specialty Chemicals industry mean.
  • A Debt to Equity ratio of 100.4% means that company has kr1.00 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Novonesis (Novozymes) A/S:

  • The MRQ is 1.004. The company is able to pay all its debts with equity. +1
  • The TTM is 1.004. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.004TTM1.0040.000
TTM1.004YOY0.994+0.010
TTM1.0045Y0.933+0.071
5Y0.93310Y0.778+0.155
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0040.768+0.236
TTM1.0040.767+0.237
YOY0.9940.744+0.250
5Y0.9330.815+0.118
10Y0.7780.839-0.061
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Novonesis generates.

  • Above 15 is considered overpriced but always compare Novonesis to the Specialty Chemicals industry mean.
  • A PE ratio of 50.39 means the investor is paying kr50.39 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Novonesis (Novozymes) A/S:

  • The EOD is 56.541. Based on the earnings, the company is expensive. -2
  • The MRQ is 50.390. Based on the earnings, the company is expensive. -2
  • The TTM is 50.390. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD56.541MRQ50.390+6.151
MRQ50.390TTM50.3900.000
TTM50.390YOY39.308+11.082
TTM50.3905Y50.611-0.221
5Y50.61110Y45.985+4.626
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
EOD56.54117.568+38.973
MRQ50.39016.582+33.808
TTM50.39016.689+33.701
YOY39.30816.451+22.857
5Y50.61119.653+30.958
10Y45.98523.917+22.068
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Novonesis (Novozymes) A/S:

  • The EOD is 135.483. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 120.744. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 120.744. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD135.483MRQ120.744+14.739
MRQ120.744TTM120.7440.000
TTM120.744YOY129.476-8.732
TTM120.7445Y86.256+34.488
5Y86.25610Y66.988+19.268
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
EOD135.4838.443+127.040
MRQ120.7448.541+112.203
TTM120.7443.394+117.350
YOY129.4761.938+127.538
5Y86.2563.299+82.957
10Y66.9882.645+64.343
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Novonesis is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Specialty Chemicals industry mean).
  • A PB ratio of 1.42 means the investor is paying kr1.42 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Novonesis (Novozymes) A/S:

  • The EOD is 1.597. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.424. Based on the equity, the company is underpriced. +1
  • The TTM is 1.424. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.597MRQ1.424+0.174
MRQ1.424TTM1.4240.000
TTM1.424YOY1.362+0.062
TTM1.4245Y1.697-0.273
5Y1.69710Y1.559+0.137
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
EOD1.5971.860-0.263
MRQ1.4241.748-0.324
TTM1.4241.791-0.367
YOY1.3621.866-0.504
5Y1.6972.262-0.565
10Y1.5592.756-1.197
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets28,391,000
Total Liabilities14,040,000
Total Stockholder Equity13,978,000
 As reported
Total Liabilities 14,040,000
Total Stockholder Equity+ 13,978,000
Total Assets = 28,391,000

Assets

Total Assets28,391,000
Total Current Assets9,462,000
Long-term Assets18,929,000
Total Current Assets
Cash And Cash Equivalents 1,116,000
Short-term Investments 40,000
Net Receivables 3,702,000
Inventory 3,627,000
Total Current Assets  (as reported)9,462,000
Total Current Assets  (calculated)8,485,000
+/- 977,000
Long-term Assets
Property Plant Equipment 12,325,000
Goodwill 1,975,000
Intangible Assets 2,557,000
Long-term Assets  (as reported)18,929,000
Long-term Assets  (calculated)16,857,000
+/- 2,072,000

Liabilities & Shareholders' Equity

Total Current Liabilities7,262,000
Long-term Liabilities6,778,000
Total Stockholder Equity13,978,000
Total Current Liabilities
Short Long Term Debt 3,036,000
Accounts payable 1,616,000
Other Current Liabilities 656,000
Total Current Liabilities  (as reported)7,262,000
Total Current Liabilities  (calculated)5,308,000
+/- 1,954,000
Long-term Liabilities
Long term Debt 4,328,000
Capital Lease Obligations Min Short Term Debt369,000
Long-term Liabilities  (as reported)6,778,000
Long-term Liabilities  (calculated)4,697,000
+/- 2,081,000
Total Stockholder Equity
Retained Earnings 13,755,000
Total Stockholder Equity (as reported)13,978,000
Total Stockholder Equity (calculated)13,755,000
+/- 223,000
Other
Capital Stock562,000
Common Stock Shares Outstanding 277,317
Net Debt 6,248,000
Net Invested Capital 13,978,000
Net Working Capital 2,200,000
Property Plant and Equipment Gross 26,219,000



6.2. Balance Sheets Structured

Currency in EUR. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-31
> Total Assets 
8,350,000
7,633,000
7,134,000
7,309,000
7,965,000
8,871,000
9,925,000
10,890,000
12,593,000
13,842,000
15,113,000
16,506,000
18,426,000
17,791,000
18,659,000
18,373,000
19,697,000
20,437,000
20,510,000
24,767,000
27,983,000
28,391,000
28,391,00027,983,00024,767,00020,510,00020,437,00019,697,00018,373,00018,659,00017,791,00018,426,00016,506,00015,113,00013,842,00012,593,00010,890,0009,925,0008,871,0007,965,0007,309,0007,134,0007,633,0008,350,000
   > Total Current Assets 
3,776,000
3,316,000
3,141,000
3,339,000
3,586,000
3,653,000
4,284,000
4,899,000
5,536,000
4,789,000
4,890,000
5,830,000
7,311,000
6,148,000
6,393,000
6,137,000
6,835,000
7,050,000
6,911,000
7,823,000
9,241,000
9,462,000
9,462,0009,241,0007,823,0006,911,0007,050,0006,835,0006,137,0006,393,0006,148,0007,311,0005,830,0004,890,0004,789,0005,536,0004,899,0004,284,0003,653,0003,586,0003,339,0003,141,0003,316,0003,776,000
       Cash And Cash Equivalents 
832,000
571,000
531,000
454,000
497,000
460,000
997,000
1,284,000
1,465,000
667,000
535,000
1,003,000
2,535,000
839,000
812,000
632,000
723,000
711,000
1,181,000
963,000
1,041,000
1,116,000
1,116,0001,041,000963,0001,181,000711,000723,000632,000812,000839,0002,535,0001,003,000535,000667,0001,465,0001,284,000997,000460,000497,000454,000531,000571,000832,000
       Short-term Investments 
166,000
115,000
93,000
151,000
177,000
0
0
0
178,000
48,000
45,000
87,000
17,000
20,000
4,000
16,000
14,000
15,000
119,000
75,000
80,000
40,000
40,00080,00075,000119,00015,00014,00016,0004,00020,00017,00087,00045,00048,000178,000000177,000151,00093,000115,000166,000
       Net Receivables 
0
0
0
0
0
1,675,000
1,614,000
1,893,000
0
0
0
2,694,000
2,575,000
3,008,000
3,089,000
2,903,000
3,278,000
3,649,000
3,227,000
3,793,000
3,454,000
3,702,000
3,702,0003,454,0003,793,0003,227,0003,649,0003,278,0002,903,0003,089,0003,008,0002,575,0002,694,0000001,893,0001,614,0001,675,00000000
       Inventory 
1,318,000
1,117,000
1,130,000
1,197,000
1,326,000
1,322,000
1,557,000
1,535,000
1,640,000
1,741,000
1,808,000
1,902,000
2,184,000
2,281,000
2,488,000
2,586,000
2,820,000
2,613,000
2,361,000
2,992,000
3,803,000
3,627,000
3,627,0003,803,0002,992,0002,361,0002,613,0002,820,0002,586,0002,488,0002,281,0002,184,0001,902,0001,808,0001,741,0001,640,0001,535,0001,557,0001,322,0001,326,0001,197,0001,130,0001,117,0001,318,000
       Other Current Assets 
1,460,000
1,513,000
1,387,000
1,537,000
1,586,000
196,000
116,000
187,000
2,253,000
2,333,000
2,502,000
2,838,000
2,575,000
3,008,000
3,089,000
2,903,000
3,278,000
3,711,000
3,250,000
3,793,000
4,317,000
0
04,317,0003,793,0003,250,0003,711,0003,278,0002,903,0003,089,0003,008,0002,575,0002,838,0002,502,0002,333,0002,253,000187,000116,000196,0001,586,0001,537,0001,387,0001,513,0001,460,000
   > Long-term Assets 
4,574,000
4,317,000
3,993,000
3,970,000
4,379,000
5,218,000
5,641,000
5,991,000
7,057,000
9,053,000
10,223,000
10,676,000
11,115,000
11,643,000
12,266,000
12,236,000
12,862,000
13,387,000
13,599,000
16,944,000
18,742,000
18,929,000
18,929,00018,742,00016,944,00013,599,00013,387,00012,862,00012,236,00012,266,00011,643,00011,115,00010,676,00010,223,0009,053,0007,057,0005,991,0005,641,0005,218,0004,379,0003,970,0003,993,0004,317,0004,574,000
       Property Plant Equipment 
3,985,000
3,783,000
3,522,000
3,477,000
3,553,000
3,842,000
4,319,000
4,804,000
5,866,000
6,557,000
7,084,000
7,135,000
7,498,000
8,162,000
8,641,000
8,926,000
9,698,000
10,212,000
9,612,000
10,185,000
12,074,000
12,325,000
12,325,00012,074,00010,185,0009,612,00010,212,0009,698,0008,926,0008,641,0008,162,0007,498,0007,135,0007,084,0006,557,0005,866,0004,804,0004,319,0003,842,0003,553,0003,477,0003,522,0003,783,0003,985,000
       Goodwill 
117,000
125,000
95,000
120,000
216,000
500,000
415,000
0
0
0
811,000
1,022,000
1,113,000
1,140,000
1,159,000
1,108,000
1,086,000
965,000
1,098,000
2,020,000
2,007,000
1,975,000
1,975,0002,007,0002,020,0001,098,000965,0001,086,0001,108,0001,159,0001,140,0001,113,0001,022,000811,000000415,000500,000216,000120,00095,000125,000117,000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
59,000
53,000
230,000
224,000
88,000
62,000
59,000
0
0
0
0
000059,00062,00088,000224,000230,00053,00059,00000000000000
       Intangible Assets 
435,000
409,000
376,000
311,000
553,000
821,000
764,000
1,124,000
1,070,000
2,221,000
1,861,000
1,842,000
1,841,000
1,536,000
1,578,000
1,324,000
1,044,000
961,000
1,456,000
3,004,000
2,691,000
2,557,000
2,557,0002,691,0003,004,0001,456,000961,0001,044,0001,324,0001,578,0001,536,0001,841,0001,842,0001,861,0002,221,0001,070,0001,124,000764,000821,000553,000311,000376,000409,000435,000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
618,000
610,000
575,000
664,000
790,000
972,000
1,190,000
1,379,000
1,676,000
1,747,000
0
01,747,0001,676,0001,379,0001,190,000972,000790,000664,000575,000610,000618,00000000000000
> Total Liabilities 
4,102,000
3,458,000
3,242,000
3,515,000
4,572,000
5,204,000
5,449,000
5,039,000
4,757,000
5,018,000
5,545,000
5,440,000
7,146,000
6,198,000
6,914,000
7,106,000
8,259,000
8,957,000
9,266,000
12,561,000
13,755,000
14,040,000
14,040,00013,755,00012,561,0009,266,0008,957,0008,259,0007,106,0006,914,0006,198,0007,146,0005,440,0005,545,0005,018,0004,757,0005,039,0005,449,0005,204,0004,572,0003,515,0003,242,0003,458,0004,102,000
   > Total Current Liabilities 
1,160,000
1,449,000
1,223,000
1,442,000
1,938,000
2,394,000
2,886,000
2,521,000
2,508,000
2,357,000
2,620,000
2,599,000
3,941,000
3,300,000
3,562,000
4,577,000
5,525,000
4,735,000
4,161,000
5,673,000
6,963,000
7,262,000
7,262,0006,963,0005,673,0004,161,0004,735,0005,525,0004,577,0003,562,0003,300,0003,941,0002,599,0002,620,0002,357,0002,508,0002,521,0002,886,0002,394,0001,938,0001,442,0001,223,0001,449,0001,160,000
       Short-term Debt 
204,000
373,000
48,000
0
0
0
0
0
0
0
243,000
92,000
594,000
74,000
89,000
971,000
1,789,000
1,543,000
136,000
122,000
123,000
0
0123,000122,000136,0001,543,0001,789,000971,00089,00074,000594,00092,000243,000000000048,000373,000204,000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
1,788,000
594,000
74,000
89,000
971,000
1,789,000
1,380,000
0
0
2,818,000
3,036,000
3,036,0002,818,000001,380,0001,789,000971,00089,00074,000594,0001,788,00000000000000
       Accounts payable 
255,000
208,000
202,000
313,000
386,000
422,000
630,000
531,000
764,000
745,000
1,044,000
976,000
1,122,000
1,189,000
1,194,000
1,341,000
1,418,000
1,117,000
1,100,000
1,490,000
1,869,000
1,616,000
1,616,0001,869,0001,490,0001,100,0001,117,0001,418,0001,341,0001,194,0001,189,0001,122,000976,0001,044,000745,000764,000531,000630,000422,000386,000313,000202,000208,000255,000
       Other Current Liabilities 
654,000
801,000
892,000
1,129,000
1,552,000
1,972,000
2,256,000
1,990,000
1,744,000
1,612,000
1,257,000
1,175,000
1,375,000
1,668,000
1,842,000
1,782,000
1,743,000
1,411,000
2,925,000
4,061,000
4,971,000
656,000
656,0004,971,0004,061,0002,925,0001,411,0001,743,0001,782,0001,842,0001,668,0001,375,0001,175,0001,257,0001,612,0001,744,0001,990,0002,256,0001,972,0001,552,0001,129,000892,000801,000654,000
   > Long-term Liabilities 
2,942,000
2,009,000
2,019,000
2,073,000
2,634,000
2,810,000
2,563,000
2,518,000
2,249,000
2,661,000
2,925,000
2,841,000
3,205,000
2,898,000
3,352,000
2,529,000
2,734,000
4,222,000
5,105,000
6,888,000
6,792,000
6,778,000
6,778,0006,792,0006,888,0005,105,0004,222,0002,734,0002,529,0003,352,0002,898,0003,205,0002,841,0002,925,0002,661,0002,249,0002,518,0002,563,0002,810,0002,634,0002,073,0002,019,0002,009,0002,942,000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
1,145,000
2,001,000
1,696,000
1,638,000
1,225,000
1,265,000
1,063,000
1,475,000
2,851,000
2,885,000
0
02,885,0002,851,0001,475,0001,063,0001,265,0001,225,0001,638,0001,696,0002,001,0001,145,00000000000000
> Total Stockholder Equity
4,062,000
4,113,000
3,828,000
3,761,000
3,359,000
3,657,000
4,465,000
5,831,000
7,824,000
8,809,000
9,555,000
11,054,000
11,269,000
11,580,000
11,732,000
11,254,000
11,425,000
11,468,000
11,233,000
11,827,000
13,837,000
13,978,000
13,978,00013,837,00011,827,00011,233,00011,468,00011,425,00011,254,00011,732,00011,580,00011,269,00011,054,0009,555,0008,809,0007,824,0005,831,0004,465,0003,657,0003,359,0003,761,0003,828,0004,113,0004,062,000
   Common Stock
754,000
754,000
726,000
696,000
650,000
650,000
650,000
650,000
650,000
650,000
650,000
639,000
639,000
626,000
620,000
610,000
594,000
582,000
570,000
564,000
562,000
0
0562,000564,000570,000582,000594,000610,000620,000626,000639,000639,000650,000650,000650,000650,000650,000650,000650,000696,000726,000754,000754,000
   Retained Earnings 
3,673,000
4,289,000
4,353,000
4,602,000
4,072,000
4,821,000
5,638,000
6,651,000
8,113,000
9,408,000
8,473,000
10,246,000
10,209,000
10,396,000
10,483,000
10,861,000
10,943,000
10,810,000
11,263,000
11,303,000
13,062,000
13,755,000
13,755,00013,062,00011,303,00011,263,00010,810,00010,943,00010,861,00010,483,00010,396,00010,209,00010,246,0008,473,0009,408,0008,113,0006,651,0005,638,0004,821,0004,072,0004,602,0004,353,0004,289,0003,673,000
   Capital Surplus 0000000000000000000000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 
-365,000
-930,000
-1,251,000
-1,537,000
-1,363,000
-1,814,000
-1,823,000
-1,470,000
-939,000
-1,249,000
432,000
169,000
421,000
558,000
629,000
-217,000
-112,000
76,000
-600,000
-40,000
213,000
0
0213,000-40,000-600,00076,000-112,000-217,000629,000558,000421,000169,000432,000-1,249,000-939,000-1,470,000-1,823,000-1,814,000-1,363,000-1,537,000-1,251,000-930,000-365,000



6.3. Balance Sheets

Currency in EUR. All numbers in thousands.




6.4. Cash Flows

Currency in DKK. All numbers in thousands.




6.5. Income Statements

Currency in DKK. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in EUR. All numbers in thousands.

Gross Profit (+$)
totalRevenue17,899,000
Cost of Revenue-8,177,000
Gross Profit9,722,0009,722,000
 
Operating Income (+$)
Gross Profit9,722,000
Operating Expense-13,435,000
Operating Income4,464,000-3,713,000
 
Operating Expense (+$)
Research Development2,017,000
Selling General Administrative3,324,000
Selling And Marketing Expenses-
Operating Expense13,435,0005,341,000
 
Net Interest Income (+$)
Interest Income90,000
Interest Expense-173,000
Other Finance Cost-66,000
Net Interest Income-149,000
 
Pretax Income (+$)
Operating Income4,464,000
Net Interest Income-149,000
Other Non-Operating Income Expenses-
Income Before Tax (EBT)3,909,0004,464,000
EBIT - interestExpense = -173,000
3,024,000
3,197,000
Interest Expense173,000
Earnings Before Interest and Taxes (EBIT)-4,082,000
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax3,909,000
Tax Provision-870,000
Net Income From Continuing Ops3,039,0003,039,000
Net Income3,024,000
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-149,000
 

Technical Analysis of Novonesis
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Novonesis. The general trend of Novonesis is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Novonesis's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Novonesis (Novozymes) A/S.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 450.60 < 458.40 < 485.90.

The bearish price targets are: 385.30 > 384.23 > 383.34.

Tweet this
Novonesis (Novozymes) A/S Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Novonesis (Novozymes) A/S. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Novonesis (Novozymes) A/S Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Novonesis (Novozymes) A/S. The current macd is -8.19806871.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Novonesis price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Novonesis. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Novonesis price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Novonesis (Novozymes) A/S Daily Moving Average Convergence/Divergence (MACD) ChartNovonesis (Novozymes) A/S Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Novonesis (Novozymes) A/S. The current adx is 40.42.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Novonesis shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Novonesis (Novozymes) A/S Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Novonesis (Novozymes) A/S. The current sar is 387.05.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Novonesis (Novozymes) A/S Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Novonesis (Novozymes) A/S. The current rsi is 45.36. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Novonesis (Novozymes) A/S Daily Relative Strength Index (RSI) ChartNovonesis (Novozymes) A/S Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Novonesis (Novozymes) A/S. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Novonesis price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Novonesis (Novozymes) A/S Daily Stochastic Oscillator ChartNovonesis (Novozymes) A/S Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Novonesis (Novozymes) A/S. The current cci is 15.44.

Novonesis (Novozymes) A/S Daily Commodity Channel Index (CCI) ChartNovonesis (Novozymes) A/S Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Novonesis (Novozymes) A/S. The current cmo is -2.7365697.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Novonesis (Novozymes) A/S Daily Chande Momentum Oscillator (CMO) ChartNovonesis (Novozymes) A/S Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Novonesis (Novozymes) A/S. The current willr is -32.39130435.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Novonesis is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Novonesis (Novozymes) A/S Daily Williams %R ChartNovonesis (Novozymes) A/S Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Novonesis (Novozymes) A/S.

Novonesis (Novozymes) A/S Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Novonesis (Novozymes) A/S. The current atr is 10.11.

Novonesis (Novozymes) A/S Daily Average True Range (ATR) ChartNovonesis (Novozymes) A/S Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Novonesis (Novozymes) A/S. The current obv is 9,711,984.

Novonesis (Novozymes) A/S Daily On-Balance Volume (OBV) ChartNovonesis (Novozymes) A/S Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Novonesis (Novozymes) A/S. The current mfi is 69.36.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Novonesis (Novozymes) A/S Daily Money Flow Index (MFI) ChartNovonesis (Novozymes) A/S Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Novonesis (Novozymes) A/S.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-07-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-07-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-07-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-31CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-08-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-23MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-26MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-09-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-09-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-17MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-25STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-09-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-30STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-01STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-10-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-30BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Novonesis (Novozymes) A/S Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Novonesis (Novozymes) A/S based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.357
Ma 20Greater thanMa 50416.760
Ma 50Greater thanMa 100444.116
Ma 100Greater thanMa 200442.827
OpenGreater thanClose425.300
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Novonesis with someone you think should read this too:
  • Are you bullish or bearish on Novonesis? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Novonesis? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Novonesis (Novozymes) A/S

I send you an email if I find something interesting about Novonesis (Novozymes) A/S.


Comments

How you think about this?

Leave a comment

Stay informed about Novonesis (Novozymes) A/S.

Receive notifications about Novonesis (Novozymes) A/S in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.